THERMO FISHER SCIENTIFIC INC.
TMONYSE · SIC 3829
$532.48
↓ -2.0%Jul 17 close · end-of-day
Price
1Y↑ +28.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$198.6B
Enterprise Value
$238.5B
P/E
29.3
P/S
4.4
P/B
3.8
EV/EBITDA
26.6
PEG
141.0
FCF Yield
3.4%
Dividend Yield
0.3%
Revenue (TTM)
$45.2B
Net Income (TTM)
$6.9B
Free Cash Flow (TTM)
$6.7B
Gross Margin
—
Operating Margin
17.5%
Net Margin
15.2%
ROE
13.2%
ROIC
8.0%
Debt / Equity
0.8
Net Cash
-$39.9B
Return 1Y
+25.8%
Company profile
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines. Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids. Laboratory Products and Services segment provides laboratory refrigerators and freezers.
- CEO
- Marc N. Casper
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 130,000
- Headquarters
- Massachusetts
- Website
- thermofisher.com
Management & directors
- Pettiti GianlucaExecutive Vice President
- Shafer Michael DExecutive Vice President
- Casper Marc NChairman & CEO
- Britt Lisa P.Sr. VP and Chief HR Officer
- Holmes Joseph R.VP & Chief Accounting Officer
- Lagarde MichelExecutive Vice President & COO
- Lowery Frederick M.Executive Vice President
- Williamson StephenRetiring Sr. VP and CFO
- Shropshire Thomas B Jr.SVP and General Counsel
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-23
TMO Q1 2026 Earnings
Period ends 2026-03-28
MetricActualYoY
Revenue$11.0B↑ +6.2%
Diluted EPS$4.43↑ +11.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $32.2B | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $7.8B | $10.0B | $8.4B | $6.9B | $7.3B | $7.7B |
| Net income | — | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B |
| Diluted EPS | $15.96 | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 |
| Operating cash flow | $8.3B | $9.3B | $9.2B | $8.4B | $8.7B | $7.8B |
| Free cash flow | $6.8B | $6.8B | $6.9B | $6.9B | $7.3B | $6.3B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 24.2% | 25.6% | 18.7% | 16.0% | 17.1% | 17.4% |
| Net margin | — | 19.7% | 15.5% | 13.9% | 14.8% | 15.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5B | $10.6B | $11.4B | $10.4B | $10.9B | $11.1B | $12.2B | $11.0B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.8B | $1.8B | $2.0B | $1.7B | $1.8B | $1.9B | $2.3B | $1.9B |
| Net income | $1.5B | $1.6B | — | $1.5B | $1.6B | $1.6B | $2.0B | $1.7B |
| Diluted EPS | $4.04 | $4.25 | $4.78 | $3.98 | $4.28 | $4.27 | $5.21 | $4.43 |
| Operating cash flow | $2.0B | $2.2B | $3.3B | $723.0M | $1.4B | $2.2B | $3.5B | $1.2B |
| Free cash flow | $1.7B | $1.9B | $2.8B | $361.0M | $1.1B | $1.8B | $3.0B | $816.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 17.3% | 17.3% | 17.7% | 16.6% | 16.9% | 17.5% | 18.5% | 16.9% |
| Net margin | 14.7% | 15.4% | — | 14.5% | 14.9% | 14.5% | 16.2% | 15.0% |
Company news
Jul 20, 2026
- 2h agoHow FBI Rapid DNA Approval Shapes Thermo Fisher Scientific’s (TMO) Long-Term Forensics Strategyfinance.yahoo.com
- 4h agoThermo Fisher (TMO) Stock May Be Undervalued As Guidance Risesfinance.yahoo.com
- 7h agoExploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings, Beyond Revenue and EPSfinance.yahoo.com
Jul 17, 2026
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-20 | WEISLER DION J | Tax withholding | 80 | $451.79 | $36,272.86 | filing |
| 2026-05-20 | WEISLER DION J | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | SPERLING SCOTT M | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | Spar Debora L | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | Lynch Karen S | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | Keith R. Alexandra | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | JOHNSON JENNIFER M | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | Jacks Tyler | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | HARRIS C MARTIN | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | CHANDY RUBY R | Award | 499 | $0.00 | $0.00 | filing |
| 2026-05-20 | Chai Nelson | Award | 499 | $0.00 | $0.00 | filing |
| 2026-04-27 | Pettiti Gianluca· President & COO | Sale | 400 | $462.66 | $185,064.00 | filing |
| 2026-03-11 | Shafer Michael D· Executive Vice President | Sale | 1,607 | $499.40 | $802,535.80 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Option exercise | 4,000 | $309.63 | $1.2M | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 1,133 | $513.71 | $582,033.43 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 570 | $514.71 | $293,384.70 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 516 | $519.13 | $267,871.08 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 411 | $512.73 | $210,732.03 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 348 | $515.64 | $179,442.72 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 264 | $519.74 | $137,211.36 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 214 | $511.78 | $109,520.92 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 201 | $516.73 | $103,862.73 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 106 | $517.83 | $54,889.98 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 99 | $509.66 | $50,456.34 | filing |
| 2026-03-05 | CASPER MARC N· Chairman & CEO | Sale | 60 | $505.76 | $30,345.60 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.